Testing of the lead candidates in treated leukemia cell cultures indicated that the JAK2 kinase inhibitors were active against both wild-type and mutant JAK2 kinase activity and caused potent inhibition of cancer cell proliferation.
Gregory Berk, chief medical officer of SuperGen, said: “The in vitro inhibition of cancer cell proliferation by our lead JAK2 kinase inhibitors demonstrates the promise that this program holds to treat both hematological cancers and solid tumors.”